---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-060536"
form_type: "8-K"
ticker: "TBPH"
cik: "0001583107"
company_name: "Theravance Biopharma, Inc."
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T02:20:01.267144+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Theravance Biopharma Q1 2024: Viatris collab revenue up 39% to $14.5M; net loss narrows to $11.7M

## Summary
- Viatris collaboration revenue of $14.5M, up 39% YoY; implied 35% share of YUPELRI net sales $19.3M, up 18%.
- Net loss of $11.7M narrowed from $22.1M YoY; non-GAAP net loss from operations $4.5M vs $14.9M.
- YUPELRI total net sales $55.2M (by Viatris), +18% YoY; hospital doses sold up 31%.
- Cash balance $100M; R&D expenses $9.0M down from $14.6M; SG&A $16.7M down from $19.2M.
- Ampreloxetine CYPRESS enrollment continues; open-label enrollment expected H2 2024; KOL event May 23.

## SEC filing metadata
- accession: 0001104659-24-060536
- form_type: 8-K
- ticker: TBPH
- cik: 0001583107
- company_name: Theravance Biopharma, Inc.
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/tm2414185d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-060536
- JSON: https://secwatch.observer/filing/0001104659-24-060536.json
- Plain text: https://secwatch.observer/filing/0001104659-24-060536.txt

## Key facts
- Earnings Releases
  Theravance Biopharma, Inc. reported the first quarter of 2024 results: revenue Total revenue for the first quarter of 2024 was $14.5 million, net income Net loss was $11.7 million.
  - Period: the first quarter of 2024
  - Revenue: Total revenue for the first quarter of 2024 was $14.5 million
  - Net income: Net loss was $11.7 million
  - Result: reported results
  source text: Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1583107/000110465924060536/0001104659-24-060536-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.